ACCC is devoted to providing up-to-date resources and education to help improve patient care and survival rates for those diagnosed with renal cell carcinoma (also known as kidney cancer).
Renal cell carcinoma is among the ten most common cancers in both men and women. Of those diagnosed with the disease, 15 – 25 percent have metastatic renal cell carcinoma (mRCC), which means the cancer has spread to other parts of the body.
Typically, renal cell carcinoma is a disease that affects older individuals; the average age at diagnosis is 64. In 2022, it is estimated that the U.S. will see about 79,000 new cases of renal cell carcinoma (50,290 in men and 28,710 in women), and that nearly 13,920 individuals will die from this disease.
Source: American Cancer Society. Key Statistics about Kidney Cancer.
This project will develop and facilitate surveys for patients and providers with the overall goal of facilitating optimized treatment options and improved care for patients diagnosed with metastatic RCC.
ACCC's Improving Quality Care in Renal Cell Carcinoma project seeks to improve the quality of care for renal cell carcinoma patients treated at community cancer programs.
This program is designed to provide a multidisciplinary care team with knowledge and resources to successfully address the practical issues and barriers associated with the integration of immunotherapies into the treatment of renal cell carcinoma.